Immunotherapy: past, present and future (Q22251059)

Europe PubMed Central

title

Immunotherapy: past, present and future (English)

0 references

1 reference

Thomas A. Waldmann

1

Thomas A.

Waldmann

1 reference

Dimensions Publication ID

Dimensions

1052480669

https://scigraph.springernature.com/pub.10.1038/nm0303-269

7 February 2023

language of work or name

English

0 references

publication date

March 2003

0 references

published in

Nature Medicine

0 references

volume

9

0 references

page(s)

269-277

0 references

issue

3

0 references

exact match

0 references

cites work

Tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Spinning molecular immunology into successful immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Strategies for designing and optimizing new generation vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Monoclonal antibodies in diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Therapeutic antibodies: magic bullets hit the target.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Human neoplasms elicit multiple specific immune responses in the autologous host

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

The makings of a tumor rejection antigen

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Myeloma proteins as tumor-specific transplantation antigens

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

DNA immunization induces protective immunity against B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Roles of heat-shock proteins in innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Fas and the art of lymphocyte maintenance

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Regulatory T cells in autoimmmunity*.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Control of homeostasis of CD8+ memory T cells by opposing cytokines.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

A humanized antibody that binds to the interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Why do we not have a cure for rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Fc receptors are required in passive and active immunity to melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

1 reference

https://api.crossref.org/works/10.1038%2FNM0303-269

7 January 2021